Skip to main content
Premium Trial:

Request an Annual Quote

Lattice Biologics Partners With Sunnybrook Research Institute on Cancer Screening Tech

NEW YORK (GenomeWeb) – Lattice Biologics announced today that it has entered into a sponsored collaboration agreement with Sunnybrook Research Institute to develop new methods and instruments for cellular measurement, as well as to validate methods for determining mechanisms of drug resistance and sensitivity.

Lattice will collaborate with Sunnybrook researchers to develop high-throughput methods and tools to screen patient-derived tumor cells within the human extracellular matrix (ECM) using Lattice's proprietary technology to replicate heterogeneous tumor microenvironments. The firm said it will aim to use these cells to test different cancer therapeutics in order to assess their effects prior to being administered to a patient.

Additional terms of the arrangement were not disclosed.

"Lattice Biologic's ECM technology is revolutionary in its unparalleled ability to accurately recreate complex tumor microenvironments because it allows us to grow biopsies from patients' own cancer tumors in the laboratory, subject the tumors to multiple anti-cancer agents, and observe the resulting behaviors all while sustaining natural conditions," Lattice CEO Guy Cook said in a statement.